BridgeMD
Compares treatment options for Epithelial Ovarian Carcinoma Stage III
Official title Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
ClinicalTrials.gov ID: NCT05737303
What this study is testing
What is nab-paclitaxel combined with carboplatin?
nab-paclitaxel combined with carboplatin is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for epithelial ovarian carcinoma stage iii.
Also referred to as paclitaxel combined with carboplatin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Epithelial ovarian cancer/tubal cancer/peritoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen...
- Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points
- Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment
- Written informed consent
- Expected survival ≥6 months
You likely can't join if
- Patients with low malignant potential ovarian tumors;
- Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;
- Patients who have previously received chemotherapy or radiotherapy for pelvic cavity;
- Patients with central nervous system metastasis or peripheral neuropathy \> grade 1;
- Patients with severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at the time of screening;
- Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval...
See the full eligibility criteria
- Epithelial ovarian cancer/tubal cancer/peritoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen, and was classified as stage III-IV according to FIGO（International...
- Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points
- Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment
- Written informed consent
- Expected survival ≥6 months
- The disease met the criteria for how well it works Evaluation of solid tumors (RECIST 1.1)
- Be able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation.
- Patients with low malignant potential ovarian tumors;
- Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;
- Patients who have previously received chemotherapy or radiotherapy for pelvic cavity;
- Patients with central nervous system metastasis or peripheral neuropathy \> grade 1;
- Patients with severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at the time of screening;
- Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); According to NYHA（New York Heart Association） criteria...
- Uncontrolled systemic infection requiring anti-infective treatment;
- Arteriovenous thrombosis events occurring within 6 months before randomization, such as cardiovascular and cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction...
- Patients who are allergic to the active ingredients or excipients of albumin paclitaxel and carboplatin for injection;
- Pregnant or lactating women;
- Those who were considered unsuitable for inclusion by the researchers.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
- Ji'nan, Shandong, China
- Hangzhou, Zhejiang, China
- Ningbo, Zhejiang, China
- Wenzhou, Zhejiang, China
- Wenzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China; Ji'nan, Shandong, China; Hangzhou, Zhejiang, China; Ningbo, Zhejiang, China; Wenzhou, Zhejiang, China; Wenzhou, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.